Global Diabetic Neuropathy Market 2014-2018

2014-05-09
Price :
Published : May-2014
No. of Pages : 55

Diabetes is usually associated with progressive damage to the nervous system, which leads to disorders collectively known as diabetic neuropathy. Diabetic neuropathy is characterized by progressive damage to the neuronal myelin sheath, which slows down nerve conduction velocity. Axonal damage associated with diabetic neuropathy decreases nerve action potential below normal physiological level, which inhibits neuronal signal transmission. About 60 to 70 percent of the diabetic population develops neuropathy, with a considerable number of cases going undiagnosed during the initial years of progression. Disease management should start with the initial diagnosis of diabetes, from educating patients to giving them regular check-ups. Diabetic neuropathy treatment involves bringing blood glucose levels within the normal range to check for further nerve damage and also additional treatment to provide symptomatic relief. Alternative therapies, which help in managing pain, such as biofeedback, meditation, acupuncture or other relaxation techniques can also be used.

TechNavio’s analysts forecast the Global Diabetic Neuropathy market will grow at a CAGR of 8.41 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Diabetic Neuropathy market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various pain management drugs administered to relieve the pain symptoms associated with diabetic neuropathy. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Diabetic Neuropathy market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio’s report, the Global Diabetic Neuropathy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Diabetic Neuropathy market landscape and its growth prospects in the coming years.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Eli Lilly and Co.
  • Janssen Pharmaceuticals Inc.
  • Pfizer Inc.

Other Prominent Vendors

  • Actavis plc
  • Cephalon Inc.
  • MEDA Pharma GmbH & Co. KG

Key Market Driver

  • Increasing Global Diabetic Population.
  • For a full, detailed list, view our report.

Key Market Challenge

  • High Failure Rate in Clinical Trials.
  • For a full, detailed list, view our report.

Key Market Trend

  • Increasing R&D Activities.
  • For a full, detailed list, view our report.

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical, Therapeutics
Publisher : Technavio
More Reports
Title Price Buy Now

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2018 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2018 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2018. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides......
$1000

Peanut Allergy: Epidemiology Forecast to 2027

Peanut Allergy: Epidemiology Forecast to 2027 Summary Peanut allergy is a type of food allergy in which the individual is allergic to peanut, which is part of the legume family. Peanut allergy is an immunoglobulin E (IgE) mediated type-I hypersensitivity reaction in which, once exposed to peanut, the body elicits an inappropriate immune response, causing the symptomology seen in allergic persons. The minimum dose of exposure to elicit an allergic response is highly variable, with some people only requiring trace amounts for a severe reaction. GlobalData epidemiologists provide a 10-year epidemiological forecast for the probable diagnosed prevalent cases of peanut allergy by age and sex, as well as the probable diagnosed prevalent cases of peanut allergy with associated comorbidity, and ......
$3995

Peritoneal Cancer Global Clinical Trials Review, H1, 2018

Peritoneal Cancer Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Peritoneal Cancer Global Clinical Trials Review, H1, 2018" provides an overview of Peritoneal Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Peritoneal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials da......
$2500

Peritonitis Global Clinical Trials Review, H1, 2018

Peritonitis Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Peritonitis Global Clinical Trials Review, H1, 2018" provides an overview of Peritonitis clinical trials scenario. This report provides top line data relating to the clinical trials on Peritonitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials ......
$2500

Periventricular Leukomalacia Global Clinical Trials Review, H1, 2018

Periventricular Leukomalacia Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Periventricular Leukomalacia Global Clinical Trials Review, H1, 2018" provides an overview of Periventricular Leukomalacia clinical trials scenario. This report provides top line data relating to the clinical trials on Periventricular Leukomalacia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary......
$2500

Peyronies Disease Global Clinical Trials Review, H1, 2018

Peyronies Disease Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Peyronies Disease Global Clinical Trials Review, H1, 2018" provides an overview of Peyronies Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Peyronies Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials da......
$2500

Dysmenorrhea Global Clinical Trials Review, H1, 2018

Dysmenorrhea Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Dysmenorrhea Global Clinical Trials Review, H1, 2018" provides an overview of Dysmenorrhea clinical trials scenario. This report provides top line data relating to the clinical trials on Dysmenorrhea. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500

Pharyngeal Neoplasm Global Clinical Trials Review, H1, 2018

Pharyngeal Neoplasm Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Pharyngeal Neoplasm Global Clinical Trials Review, H1, 2018" provides an overview of Pharyngeal Neoplasm clinical trials scenario. This report provides top line data relating to the clinical trials on Pharyngeal Neoplasm. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical t......
$2500

Hyperthyroidism Global Clinical Trials Review, H1, 2018

Hyperthyroidism Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Hyperthyroidism Global Clinical Trials Review, H1, 2018" provides an overview of Hyperthyroidism clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperthyroidism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

Phenylketonuria (PKU) Global Clinical Trials Review, H1, 2018

Phenylketonuria (PKU) Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Phenylketonuria (PKU) Global Clinical Trials Review, H1, 2018" provides an overview of Phenylketonuria (PKU) clinical trials scenario. This report provides top line data relating to the clinical trials on Phenylketonuria (PKU). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Cl......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy